ArticleNeuroscience insights2020
Scopoletin: Antiamyloidogenic, Anticholinesterase, and Neuroprotective Potential of a Natural Compound Present in
Article in Neuroscience insights, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Natural compounds as multitarget agents in Alzheimer's diseases: evidence fromFrontiers in pharmacology · 2026Pooled it
- Unlocking the Potential ofBiology · 2026Review
- Multicomponent Green Synthesis Involving Aryl Aldehydes and Trapped Enols: Dimerization over Cyclization.ACS omega · 2026Article
- Pharmacological Activity of Scopoletin: Deciphering the Potential of Coumarins in Cognitive Dysfunction.Current drug research reviews · 2026Review
- Potential of MAO-B Inhibitors with Multi-target Inhibition and Antioxidant Properties for the Treatment of Neurodegenerative Disorders.Mini reviews in medicinal chemistry · 2026Review
- Anti-cancer Potential of Scopoletin Derivatives Across Diverse Cancer Cell Lines: A Comprehensive Review.Current drug discovery technologies · 2026Review
- Multitarget 8-methoxypsoralens against Alzheimer's disease: extraction, synthesis,Future medicinal chemistry · 2025Article
- Scopoletin: a review of its pharmacology, pharmacokinetics, and toxicity.Frontiers in pharmacology · 2024Review
- Recent Advancements in Nanocarrier-assisted Brain Delivery of Phytochemicals Against Neurological Diseases.Neurochemical research · 2023Review
- Efficacy of Green Synthesized Nanoparticles in Photodynamic Therapy: A Therapeutic Approach.International journal of molecular sciences · 2023Review
- Photoactive Herbal Compounds: A Green Approach to Photodynamic Therapy.Molecules (Basel, Switzerland) · 2022Review
- Advances in biosynthesis of scopoletin.Microbial cell factories · 2022Review
- An insight into polyscopoletin electrosynthesis by a quality-by-design approach.Journal of materials science · 2022Article
- Protective Mechanisms of Nootropic Herb Shankhpushpi (Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Umbelliferyloxymethyl phosphonate compounds-weakly binding zinc ionophores with neuroprotective properties.Dalton transactions (Cambridge, England : 2003) · 2021Article
- Non-Alkaloid Cholinesterase Inhibitory Compounds from Natural Sources.Molecules (Basel, Switzerland) · 2021Review
- Review
- Inhibition of Butyrylcholinesterase and Human Monoamine Oxidase-B by the Coumarin Glycyrol and Liquiritigenin Isolated fromMolecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is characterized by depositions of amyloid β (Aβ) peptides aggregates resulting in plaques formation in the central nervous system (CNS). This study evaluates the disease-modifying potential of scopoletin against multiple factors associated with AD such as cholinesterase enzymes, Aβ peptides, and neuroprotective properties against Aβ- and H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.